167 related articles for article (PubMed ID: 33586037)
1. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
3. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
5. The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
Dankert JT; Wiesehöfer M; Czyrnik ED; Singer BB; von Ostau N; Wennemuth G
PLoS One; 2018; 13(7):e0200472. PubMed ID: 30001402
[TBL] [Abstract][Full Text] [Related]
6. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
7. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review.
Acosta-Gonzalez G; Qin J; Wieczorek R; Melamed J; Deng FM; Zhou M; Makarov D; Ye F; Pei Z; Pincus MR; Lee P
Am J Clin Exp Urol; 2014; 2(4):337-42. PubMed ID: 25606580
[TBL] [Abstract][Full Text] [Related]
8. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
10. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.
Kryvenko ON; Williamson SR; Trpkov K; Gupta NS; Athanazio D; Selig MK; Smith PT; Magi-Galluzzi C; Jorda M
Virchows Arch; 2017 Jan; 470(1):47-54. PubMed ID: 27743032
[TBL] [Abstract][Full Text] [Related]
11. Specificities of small cell neuroendocrine prostate cancer: Adverse prognostic value of TTF1 expression.
Cancel M; Castellier C; Debiais-Delpech C; Charles T; Rozet F; Rioux-Leclercq N; Mathieu R; Beltjens F; Cormier L; Bruyère F; Fromont G
Urol Oncol; 2021 Jan; 39(1):74.e17-74.e23. PubMed ID: 32739231
[TBL] [Abstract][Full Text] [Related]
12. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
15. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
[No Abstract] [Full Text] [Related]
16. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.
Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC
Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
20. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.
Sotomayor P; Godoy A; Smith GJ; Huss WJ
Prostate; 2009 Mar; 69(4):401-10. PubMed ID: 19058139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
